or search on
|Title:||Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study|
|Authors:||Shi JF; Chen JF; Canfell K; Feng XX; Ma JF; Zhang YZ; Zhao F; Rong Li; Li Ma; Li ZF; Lew JB; Ning Y; Qiao YL|
|Categories:||Cancer Control, Survivorship, and Outcomes Research - Health Services, Economic and Health Policy Analyses|
Cancer Type - Cervical Cancer
|Journal Title:||BMC Health Services Research|
|Abstract:||Abstract Background Cost estimation is a central feature of health economic analyses. The aim of this study was to use a micro-costing approach and a societal perspective to estimate aggregated costs associated with cervical cancer screening, diagnosis and treatment in rural China. Methods We assumed that future screening programs will be organized at a county level (population ~250,000), and related treatments will be performed at county or prefecture hospitals; therefore, this study was conducted in a county and a prefecture hospital in Shanxi during 2008–9. Direct medical costs were estimated by gathering information on quantities and prices of drugs, supplies, equipment and labour. Direct non-medical costs were estimated via structured patient interviews and expert opinion. Results Under the base case assumption of a high-volume screening initiative (11,475 women screened annually per county), the aggregated direct medical costs of visual inspection, self-sampled careHPV (Qiagen USA) screening, clinician-sampled careHPV, colposcopy and biopsy were estimated as US$2.64,$7.49,$7.95,$3.90 and $5.76, respectively. Screening costs were robust to screening volume (<5% variation if 2,000 women screened annually), but costs of colposcopy/biopsy tripled at the lower volume. Direct medical costs of Loop Excision, Cold-Knife Conization and Simple and Radical Hysterectomy varied from $61–544, depending on the procedure and whether conducted at county or prefecture level. Direct non-medical expenditure varied from $0.68–$3.09 for screening/diagnosis and $83–$494 for pre-cancer/cancer treatment. Conclusions Diagnostic costs were comparable to screening costs for high-volume screening but were greatly increased in lower-volume situations, which is a key consideration for the scale-up phase of new programs. The study’s findings will facilitate cost-effectiveness evaluation and budget planning for cervical cancer prevention initiatives in China.|
|Division:||Cancer Research Division|
|Funding Body:||This project was funded by Chinese Ministry of Science and Technology’s program “National Key Technology R&D Program in the 11th Five-Year Plan” (2006BAI02A15). Dr. Shi was funded by a UICC American Cancer Society Beginning Investigators Fellowship (ACS/09/008) and by Cancer Council NSW, Australia. KC received salary support from the National Health and Medical Research Council of Australia (CDF #1082989).|
|Appears in Collections:||Research Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.